Citations

Clear

3042 citation(s) found for "Kumar, S".

Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas
Grande, Joseph P. , Roche, Patrick C. , Kumar, Rajiv , Kumar, Rajiv , Johnson, Julie A.

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | December 21, 2017 | Volume: 267 | Issue: 3 | Pages: E356-E360

10.1152/ajpendo.1994.267.3.e356 | PMID 7943215 Get It

1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] is required for normal glucose-stimulated insulin release from pancreatic beta-cells. Biochemical characterization techniques have demonstrated the presence of the 1,25(OH)2D3 receptor (VDR) in homogenates of whole pancreas. Autoradiographic studies using radiolabeled 1,25(OH)2D3 suggest that the VDR is localized to beta-cells but are inconclusive. We used immunohistochemical techniques to stain serial sections from both human and rat pancreas with polyclonal antibodies to human VDR, chick calbindin D28k, insulin, glucagon, and somatostatin. VDR was present in the islet cells and also at low levels in acinar cells of the human and rat pancreas. Calbindin D28k was distributed in a manner similar to the VDR in pancreatic islets but was not present in acini. These results show for the first time that VDR and calbindin D28k are present in human pancreatic tissue. VDR and calbindin D28k are focally distributed throughout pancreatic islet cell types in humans and rats; VDR is also present in the exocrine pancreas. These findings suggest that 1,25(OH)2D3 may influence both endocrine and exocrine pancreatic function.
Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies
Shen, Jiayin , Hu, Yingwen, Putt, Karson S. , Han, Haiyong , Visscher, Daniel W., Murphy, Linda M., Singhal, Sunil Kumar , Low, Philip S.

Mayo Clinic

Oncotarget | December 16, 2017 | Volume: 9 | Issue: 4 | Pages: 4485-4495

10.18632/oncotarget.23321 | PMID 29435118 Get It

Incidence and Predictors of Readmissions in Acute Pancreatitis
Garg, Sushil Kumar , Campbell, James P. , Anugwom, Chimaobi M. , Wadhwa, Vaibhav , Singh, Rajeshwar, Gupta, Nancy , Sanaka, Madhusudhan R.

Mayo Clinic

Pancreas | December 5, 2017 | Volume: 47 | Issue: 1 | Pages: 46-54

10.1097/mpa.0000000000000952 | PMID 29215534 Get It

Objectives Acute pancreatitis (AP) is a common cause for hospitalization, and readmission is common, with variable associated risk factors for readmission. Here, we assessed the incidence and risk factors for readmission in AP in a large national database. Methods We analyzed data from the National Readmission Database during the year 2013. Index admissions with a primary discharge diagnosis of AP using the International Classification of Diseases, Ninth Revision, Clinical Modification were identified from January to November to identify 30-day readmission rates. Demographic, hospital, and clinical diagnoses were included in multivariate regression analysis to identify readmission risk factors. Results We identified 243,816 index AP discharges with 39,623 (16.2%) readmitted within 30 days. The most common reason for readmission was recurrent AP (41.5%). Increased odds of all-cause readmission were associated with younger age, nonhome discharge, increasing Charlson Comorbidity Index, and increased length of stay. Cholecystectomy during index admission was associated with reduced all-cause and recurrent AP readmissions (odds ratios of 0.5, and 0.35, respectively). Conclusions Readmission for AP is common, most often due to recurrent AP. Multiple factors, including cholecystectomy, during index admission, are associated with significantly reduced odds of all-cause and recurrent AP readmissions.
Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection
Eby, Elizabeth L. , Brown, Benedict, Lyon, Julie, Eggington, Simon , Kumar, Gayathri, Fenwick, Elisabeth, Sohail, M. Rizwan , Wright, David J. , Sohail, M Rizwan , Kay, Gemma L.

Mayo Clinic

Journal of Medical Economics | November 24, 2017 | Volume: 21 | Issue: 3 | Pages: 294-300

10.1080/13696998.2017.1409227 | PMID 29171319 Get It

Procedural trends, outcomes, and readmission rates pre‐and post‐FDA approval for MitraClip from the National Readmission Database (2013–14)
Panaich, Sidakpal , Arora, Shilpkumar , Badheka, Apurva, Kumar, Varun , Maor, Elad , Raphael, Claire E. , Deshmukh, Abhishek , Reeder, Guy S., Eleid, Mackram F. , Rihal, Charanjit S. , Panaich, Sidakpal S, Raphael, Claire , Eleid, Mackram F , Panaich, Sidakpal S , Maor, Elad , Rihal, Charanjit S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | November 20, 2017 | Volume: 91 | Issue: 6 | Pages: 1171-1181

10.1002/ccd.27366 | PMID 29152829 Get It

AbstractBackgroundThere are sparse clinical data on the procedural trends, outcomes and readmission rates following FDA approval and expansion of Transcatheter mitral valve repair/MitraClip®. Whether a complex new technology can be disseminated safely and quickly is controversial.MethodsThe study cohort was derived from the National Readmission Data (NRD) 2013–14. MitraClip® was identified using appropriate International Classification of Diseases, 9th Revision, Clinical Modification (ICD‐9‐CM) codes. The primary outcome was a composite of in‐hospital mortality + procedural complications. Secondary outcome included 30‐day readmissions. Hierarchical two level logistic models were used to evaluate study outcomes.ResultsOur analysis included 2003 MitraClip® procedures. Overall in‐hospital mortality was 3.9%. As expected, there was a significant increase in procedural volume post‐FDA approval. Importantly, a corresponding downward trend in mortality and procedural complications was observed. Significant predictors of in‐hospital mortality and procedural complications included the use of vasopressors (P <0.001) and hemodynamic support (P < 0.001). Higher hospital volume (≥10 MitraClips/year) was associated with lower in‐hospital mortality and complications (P = 0.02). There were 304 (15.1%) 30‐day readmissions, with heart failure being the most common cause of readmission. Elective procedures had lower in‐hospital mortality (P < 0.001) and lower readmission rates (P = 0.011) compared with nonelective procedures.ConclusionA significant increase in MitraClip® procedural volumes occurred post‐FDA approval. Overall morbidity and mortality were low and trended downwards. Hospital procedure volume ≥10 cases were associated with lower mortality and overall complication rates. These data suggest a successful roll out of a very complex novel structural heart procedure.
Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder
Amare, Azmeraw T. , Schubert, Klaus Oliver , Clark, Scott R. , Papiol, Sergi , Heilbronner, Urs , Degenhardt, Franziska , Tekola‐Ayele, Fasil , Hsu, Yi‐Hsiang , Shekhtman, Tatyana , Adli, Mazda , Akula, Nirmala , Akiyama, Kazufumi , Ardau, Raffaella , Arias, Bárbara , Aubry, Jean‐Michel , Bhattacharjee, Abesh Kumar, Benabarre, Antonio , Bengesser, Susanne , Birner, Armin , Brichant‐Petitjean, Clara, Cervantes, Pablo , Chen, Hsi‐Chung , Chillotti, Caterina , Cichon, Sven , Cruceanu, Cristiana , Czerski, Piotr M. , Dalkner, Nina , Zompo, Maria Del , Étain, Bruno , Falkai, Peter , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Fullerton, Janice M. , Gard, Sébastien, Grigoroiu‐Serbânescu, Maria , Grof, Paul , Hashimoto, Ryota , Jamain, Stéphane , Jiménez, Esther , Kahn, Jean‐Pierre, Kassem, Layla, Kuo, Po‐Hsiu , Kato, Tadafumi , Kittel‐Schneider, Sarah , Kliwicki, Sebastian , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Leckband, Susan G. , Tortorella, Alfonso , Manchia, Mirko , Martinsson, Lina , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , Novák, Tomáš , O’Donovan, Claire , Ozaki, Norio , Ösby, Urban, Pfennig, Andrea , Potash, James B. , Reif, Andreas , Reininghaus, Eva Z. , Schalling, Martin , Schofield, Peter R. , Schweizer, Barbara , Severino, Giovanni , Shilling, Paul D. , Shimoda, Katzutaka, Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Stopková, Pavla , Maj, Mario , Turecki, Gustavo , Vieta, Eduard , Volkert, Julia, Zandi, Peter P. , Bauer, Michael , Alda, Martin , McMahon, Francis J. , Etain, B , Vieta, E , Schofield, Peter R , Cichon, Sven , Nöthen, Markus M , Alda, Martin , Fullerton, Janice M , Hou, Liping , Backlund, Lena , Bellivier, Frank , Biernacka, Joanna M. , Dalkner, Nina , Dayer, Alexandre G. , DePaulo, J Raymond , Garnham, Julie , Goes, Fernando , Hauser, Joanna , Herms, Stefan , Hoffmann, Per , Hofmann, Andrea , Kelsoe, John R , König, Barbara , Kusumi, Ichiro , McElroy, Susan L. , Colom, Francesc , Monteleone, Palmiero , Nievergelt, Caroline M , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Squassina, Alessio , Witt, Stephanie H. , Wright, A. Jordan , Mitchell, Philip B , Rietschel, Marcella , Schulze, Thomas , Baune, Bernhard , Amare, Azmeraw , Papiol, Sergi , Heilbronner, Urs , Chen, Hsi-Chung , Cruceanu, Cristiana , Czerski, Piotr , Jamain, Stéphane , Grigoroiu-Serbanescu, Maria , Kuo, Po-Hsiu , Kittel-Schneider, Sarah , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Novak, Tomas , Reif, Andreas , Stopkova, Pavla , Turecki, Gustavo , McMahon, Francis , Arias, Bárbara , Hashimoto, Ryota , Ozaki, Norio , Schubert, Klaus Oliver , Kato, Tadafumi , Mitjans, Marina , Manchia, Mirko

Mayo Clinic

JAMA Psychiatry | November 15, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamapsychiatry.2017.3433 | PMID 29121268 Get It

Impact of Patient Distance From Ventricular Assist Device–Implanting Center on Short- and Long-Term Outcomes
Shah, Palak , Singh, Ramesh , Stulak, John M., Dardas, Todd , Mokadam, Nahush A. , Salerno, Christopher T. , Cowger, Jennifer , Dunlay, Shannon M. , Ravichandran, Ashwin Kumar , Aaronson, Keith D. , Pagani, Francis D. , Shah, Palak

Mayo Clinic

ASAIO Journal | November 7, 2017 | Volume: 64 | Issue: 6 | Pages: 721-726

10.1097/mat.0000000000000717 | PMID 29117042 Get It

Highly specialized left ventricular assist device care is not readily available in many areas, potentially limiting access to therapy. This retrospective analysis examines the relationship of outcomes by patient distance from implanting left ventricular assist device center within the Mechanical Circulatory Support Research Network. Zip codes were used to calculate patient distance, with the primary outcome of interest being 3-year survival by distance from the surgical center. Secondary outcomes included 90-day survival and incident event rates for the following: gastrointestinal bleeding, infection, cerebral event, and pump thrombosis. Across the four centers, there were 1184 patients supported for a median of 486 days. Overall survival was 91 ± 0.8% at 90 days and 61 ± 1.9% at 3 years, with worse 3-year survival in those living >90 vs . ≤90 miles from the ventricular assist device implant center (55 ± 3.0% vs . 64 ± 2.5, p = 0.019). Patients living >90 miles from an implant center were older, more likely to be implanted for destination therapy support, had a prior sternotomy, and had worse renal function than those living closer ( p <0.05 for all). After adjusting for these factors, albumin and center of implant, the hazard ratio did not reach statistical significance (hazard ratio = 1.2; p = 0.14). Except for gastrointestinal bleeding, the event rates for the secondary outcomes were higher for those living closer to the implanting center. Protocols should be designed for more frequent follow-up and increased shared care opportunities to ensure optimal outcomes are achieved in distant patients.
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis
Puri, Puneet , Liangpunsakul, Suthat , Christensen, Jeffrey E. , Shah, Vijay H. , Kamath, Patrick S. , Katz, Barry P., Yu, Qigui , Kumar, Divya P. , Mirshahi, Faridoddin , Radaeva, Svetlana , Chalasani, Naga , Crabb, David W. , Gores, Gregory J. , Walker, Sue , Comerford, Megan , Borst, Andrew J. , Sanyal, Arun J.

Mayo Clinic

Hepatology | October 30, 2017 | Volume: 67 | Issue: 4 | Pages: 1284-1302

10.1002/hep.29623 | PMID 29083504 Get It

Intestinal dysbiosis is implicated in alcoholic hepatitis (AH). However, changes in the circulating microbiome, its association with the presence and severity of AH, and its functional relevance in AH is unknown. Qualitative and quantitative assessment of changes in the circulating microbiome were performed by sequencing bacterial DNA in subjects with moderate AH (MAH) (n = 18) or severe AH (SAH) (n = 19). These data were compared with heavy drinking controls (HDCs) without obvious liver disease (n = 19) and non–alcohol‐consuming controls (NACs, n = 20). The data were related to endotoxin levels and markers of monocyte activation. Linear discriminant analysis effect size (LEfSe) analysis, inferred metagenomics, and predictive functional analysis using PICRUSt were performed. There was a significant increase in 16S copies/ng DNA both in MAH ( P < 0.01) and SAH ( P < 0.001) subjects. Compared with NACs, the relative abundance of phylum Bacteroidetes was significantly decreased in HDCs, MAH, and SAH ( P < 0.001). In contrast, all alcohol‐consuming groups had enrichment with Fusobacteria ; this was greatest for HDCs and decreased progressively in MAH and SAH. Subjects with SAH had significantly higher endotoxemia ( P = 0.01). Compared with alcohol‐consuming groups, predictive functional metagenomics indicated an enrichment of bacteria with genes related to methanogenesis and denitrification. Furthermore, both HDCs and SAH showed activation of a type III secretion system that has been linked to gram‐negative bacterial virulence. Metagenomics in SAH versus NACs predicted increased isoprenoid synthesis via mevalonate and anthranilate degradation, known modulators of gram‐positive bacterial growth and biofilm production, respectively. Conclusion: Heavy alcohol consumption appears to be the primary driver of changes in the circulating microbiome associated with a shift in its inferred metabolic functions. (H epatology 2018;67:1284‐1302).
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
Abeykoon, Jithma P. , Paludo, Jonas , King, Rebecca L. , Ansell, Stephen M. , LaPlant, Betsy, Halvorson, Alese E. , Gonsalves, Wilson I. , Dingli, David , Lacy, Martha Q. , He, Rong , Kourelis, Taxiarchis , Reeder, Craig B. , Novak, Anne J. , McPhail, Ellen D. , Viswanatha, David S., Witzig, Thomas E. , Go, Ronald S. , Leung, Nelson , Lin, Yi , Thompson, Carrie A. , Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , LaPlant, Betsy R, Gonsalves, Wilson , Witzig, T.E. , Go, Ronald S , Buadi, Francis K. , Leung, Nelson , McPhail, Ellen Darcy , Paludo, Jonas , Dingli, David , Lin, Yi , Gertz, Morie A. , Fang, Hong , Rajkumar, S. Vincent , Habermann, Thomas M. , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | October 28, 2017 | Volume: 93 | Issue: 2 | Pages: 187-194

10.1002/ajh.24955 | PMID 29080258 Get It

AbstractWaldenström macroglobulinemia (WM) is an immunoglobulin M‐associated lymphoma, with majority of cases demonstrating MYD88 locus alteration, most commonly, MYD88L265P. Owing to low prevalence of the wild‐type (WT) MYD88 genotype in WM, clinically relevant data in this patient population are sparse, with one study showing nearly a 10‐fold increased risk of mortality in this subgroup compared to patients with MYD88L265P mutation. We studied a large cohort of patients with MYD88L265P and MYD88WT WM, evaluated at Mayo Clinic, Rochester, between 1995 and 2016, to specifically assess the impact of these genotypes on clinical course. Of 557 patients, MYD88L265P mutation status, as determined by allele‐specific polymerase chain reaction, was known in 219, and 174 (79%) of those exhibited MYD88L265P, 157 of 174 patients had active disease. Of 45 (21%) patients with MYD88WT genotype, 44 had active disease. The estimated median follow‐up was 7.0 years; median overall survival was 10.2 years (95% CI: 8.4‐16.5) for MYD88L265P versus 13.9 years (95% CI: 6.4‐29.3) for the MYD88WT (P = 0.86). The time‐to‐next therapy from frontline treatment and the presenting features were similar in the two patient populations. For patients with smoldering WM at diagnosis, the median time‐to‐progression to active disease was 2.8 years (95% CI: 2.2‐3.8) in the MYD88L265P cohort and 1.9 years (95% CI: 0.7‐3.1) in the MYD88WT cohort (P = 0.21). The frequency of transformation to high‐grade lymphoma, or the development of therapy‐elated myelodysplastic syndrome was higher in the MYD88WT cohort (16% versus 4% in the MYD88L265P, P = 0.009). In conclusion, MYD88L265P mutation does not appear to be a determinant of outcome, and its presence may not be a disease‐defining feature in WM. Our findings warrant external validation, preferably through prospective studies.
Prevalence and Natural History of Superficial Siderosis
Pichler, Michael, Vemuri, Prashanthi , Aakre, Jeremiah A. , Flemming, Kelly D. , Brown, Robert D. , Kumar, Neeraj , Kantarci, Kejal , Kremers, Walter K. , Mielke, Michelle M. , Jack, Clifford R. , Petersen, Ronald C. , Lowe, Val J. , Graff‐Radford, Jonathan , Aakre, Jeremiah, Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Kantarci, Kejal , Rabinstein, Alejandro A. , Knopman, David S. , Kremers, Walter K , Flemming, Kelly D

Mayo Clinic

Stroke | October 26, 2017 | Volume: 48 | Issue: 12 | Pages: 3210-3214

10.1161/strokeaha.117.018974 | PMID 29070715 Get It

Background and Purpose— Superficial siderosis (SS) is characterized by hemosiderin deposition in the superficial layers of the central nervous system and can be seen during postmortem examination or with iron-sensitive magnetic resonance imaging techniques. The distribution of SS may predict the probable underlying cause. This study aimed to report the prevalence and natural history of SS in a population-based study. Methods— Brain magnetic resonance imaging scans from the MCSA (Mayo Clinic Study of Aging), a population-based study of residents 50 to 89 years of age in Olmsted County, Minnesota, were reviewed. Participants with imaging consistent with SS were identified from 2011 through 2016. An inverse probability weighting approach was used to convert our observed frequencies to population prevalence of SS. Additional data abstracted included amyloid positron emission tomography, Apolipoprotein E genotype, coexisting cerebral microbleeds, and extent of SS. Results— A total of 1412 participants had eligible magnetic resonance imaging scans. Two participants had infratentorial SS, restricted to the posterior fossa. Thirteen participants had cortical SS involving the cerebral convexities (7 focal and 6 disseminated). Only 3 of the participants with cortical SS (23%) also had cerebral microbleeds. The population prevalence of SS was 0.21% (95% confidence interval, 0–0.45) in those 50 to 69 years old and 1.43% (confidence interval, 0.53–2.34) in those over 69 years old. Apolipoprotein E ε2 allele was more common in those with SS (57.1% versus 15.0%; P <0.001). Compared with participants without SS, those with SS were also more likely to have a positive amyloid positron emission tomographic scan (76.9% versus 29.8%; P <0.001). Conclusions— SS may be encountered in the general elderly population. The association with increased amyloid burden and Apolipoprotein E ε2 genotype supports cerebral amyloid angiopathy as the most common mechanism. Longitudinal follow-up is needed to evaluate the risk of subsequent hemorrhage in cases of incidentally discovered SS.